摘要目的 探讨多模式组合透析对维持性血液透析(MHD)患者血Klotho蛋白、成纤维细胞生长因子23(FGF-23)、脑钠肽(BNP)水平的影响.方法 采用前瞻性随机对照研究(RCT)方法,选择2015年12月至2016年12月在贵阳市第二人民医院肾内科血液净化中心接受MHD>3个月的120例慢性肾衰竭(CRF)尿毒症患者,按随机数字表法分为血液透析(HD)组(每月8次HD)、HD+血液滤过(HF)组(每月8次HD+每月1次HF)、HD+HF+血液灌流(HP)组(每月8次HD+每月4次HF+每月1次HP),每组40例.所有患者入组前及入组后6个月、12个月在体外循环管路静脉端采血,采用酶联免疫吸附试验(ELISA)检测血清Klotho蛋白及FGF-23水平,采用电化学发光法检测血清BNP水平.结果 120例MHD患者最终均纳入分析,无中途退出、撤出病例.3组患者入组前血清Klotho蛋白、FGF-23、BNP水平差异无统计学意义(均P>0.05).与入组前比较:3组患者入组后血清Klotho水平均呈持续升高趋势,且HD+HF+HP组>HD+HF组>HD组(μg/L:6个月为2.59±0.61、1.63±0.35、1.13±0.26,F=119.374,P=0.000;12个月为6.98±1.21、3.57±1.03、2.12±0.43,F=275.675,P=0.000);而FGF-23水平均呈持续下降趋势,且HD+HF+HP组<HD+HF组<HD组(ng/L:6个月为69.22±38.26、132.28±61.18、178.50±74.64,F=33.509,P=0.000;12个月为32.81±17.32、87.93±43.27、146.33±69.28,F=55.466,P=0.000);3组间血清BNP水平也表现出与FGF-23相同的变化趋势(ng/L:6个月为4083.39±2864.53、7245.69±4643.81、7969.12±5360.85,F=8.758,P=0.000;12个月为1521.86±894.63、4554.32±1969.84、5013.89±2033.64,F=49.003,P=0.000).结论 多模式组合透析能提高接受MHD的CRF尿毒症患者体内Klotho蛋白水平,降低FGF-23、BNP水平.

abstractsObjective To discuss the effects of multimodal combination dialysis on Klotho protein, fibroblast growth factor-23 (FGF-23) and brain natriuretic peptide (BNP) in patients with maintenance hemodialysis (MHD). Methods A randomized controlled trial (RCT) was conducted. 120 patients who was diagnosed with chronic renal failure (CRF) uremia receiving MHD over 3 months admitted to Blood Purification Centre of Department of Nephrology of the Second People's Hospital of Guiyang from December 2015 to December 2016 were enrolled, who were randomly divided into hemodialysis (HD) group (HD for 8 times a month), HD + hemofiltration (HF) group (HD for 8 times a month + HF once a month), and HD + HF + hemoperfusion (HP) group (HD for 8 times a month + HF for 4 times a month + HP once a month), with 40 patients in each group. Before and after treatment for 6 months and 12 months, blood was taken from venous circuit tube, the serum Klotho protein and FGF-23 levels were determined by enzyme linked immunosorbent assay (ELISA), and the serum BNP level was determined by electrochemiluminescence. Results 120 patients with MHD were enrolled in the final analysis without withdrawal. There were no significant differences in the levels of Klotho protein, FGF-23, or BNP before enrollment among the three groups (all P > 0.05). Compared with those before enrollment, the levels of serum Klotho protein after enrollment in three groups showed a sustained upward tendency, which were higher in HD + HF + HP group than in HD + HF group and HD group (μg/L: 2.59±0.61, 1.63±0.35, 1.13±0.26 at 6 months, F = 119.374, P = 0.000; 6.98±1.21, 3.57±1.03, 2.12±0.43 at 12 months, F = 275.675, P = 0.000); the levels of FGF-23 showed a sustained downward tendency, which were lower in HD + HF + HP group than in HD + HF group and HD group (ng/L: 69.22±38.26, 132.28±61.18, 178.50±74.64 at 6 months, F = 33.509, P = 0.000; 32.81±17.32, 87.93±43.27, 146.33±69.28 at 12 months, F = 55.466, P = 0.000);the BNP showed a similar tendency as FGF-23 (ng/L: 4083.39±2864.53, 7245.69±4643.81, 7969.12±5360.85 at 6 months, F = 8.758, P = 0.000; 1521.86±894.63, 4554.32±1969.84, 5013.89±2033.64 at 12 months, F = 49.003, P = 0.000). Conclusion Multimodal combination dialysis can increase the Klotho protein level, and decrease the levels of FGF-23 and BNP in MHD patients with CRF uremia.